Literature DB >> 12565775

Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.

Franco Di Silverio1, Vincenzo Gentile, Anna De Matteis, Gianna Mariotti, Voria Giuseppe, Pastore Antonio Luigi, Alessandro Sciarra.   

Abstract

OBJECTIVES: We analyze our experience on BPH through 20 years of histopathological examinations performed by the same pathologist.
METHODS: We retrospectively reviewed all histopathological examinations performed from January 1979 to December 1998 in patients undergoing surgery in our urological clinic who were diagnosed with BPH. We limited our evaluation to the following variables in each BPH case analyzed: inflammatory aspects associated with BPH, presence of focal acinar atrophy, atypical adenomatous hyperplasia (AAH), prostatic intraepithelial neoplasia (PIN), incidental prostate carcinoma (IC). These histological variables were analyzed according to some clinical parameters such as age, prostate volume and serum PSA.
RESULTS: The study population was comprised of 3942 cases with histological diagnosis of BPH. The mean patient age was 68.85+/-7.67 years. In particular, inflammatory aspects were associated with BPH in a high percentage of cases (43.1% =1700 cases), predominantly as chronic inflammation. Observation of focal acinar atrophy significantly increased according to patient decade of age (p=0.027). There was a significant trend to increase with age decades (p=0.036) for high grade PIN. A significant difference was found in IC (T1a, T1b) distribution in the different decades of age and especially in regards to both T1a and T1b tumors, there was a trend to increase with patient age (p=0.020 and p=0.025, respectively). On the contrary, the distribution of inflammatory aspects (p<0.001) and AAH (p=0.003) significantly varied according to prostate volume, and particularly in regards to chronic inflammation, there was a trend to increase depending on the prostate volume (p=0.002). Only the presence of T1b tumor but not of the other histological parameters associated to BPH, was able to significantly influence serum PSA.
CONCLUSION: In our analysis different histological variables associated to BPH are differently influenced by the age of patients and prostate volume, and they differently influence serum PSA levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565775     DOI: 10.1016/s0302-2838(02)00548-1

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  82 in total

Review 1.  Inflammation and benign prostatic hyperplasia: clinical implications.

Authors:  Bilal Chughtai; Richard Lee; Alexis Te; Steven Kaplan
Journal:  Curr Urol Rep       Date:  2011-08       Impact factor: 3.092

Review 2.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

3.  Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study.

Authors:  David F Penson; Heather M Munro; Lisa B Signorello; William J Blot; Jay H Fowke
Journal:  J Urol       Date:  2011-10-20       Impact factor: 7.450

4.  Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Siobhan Sutcliffe; Robert L Grubb Iii; Elizabeth A Platz; Lawrence R Ragard; Thomas L Riley; Sally S Kazin; Richard B Hayes; Ann W Hsing; Gerald L Andriole
Journal:  BJU Int       Date:  2012-03-19       Impact factor: 5.588

5.  Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Authors:  Opal Lin-Tsai; Peter E Clark; Nicole L Miller; Jay H Fowke; Omar Hameed; Simon W Hayward; Douglas W Strand
Journal:  Prostate       Date:  2014-02-05       Impact factor: 4.104

Review 6.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

7.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

Review 8.  A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

Authors:  Chris Mullins; M Scott Lucia; Simon W Hayward; Jeannette Y Lee; Jonathan M Levitt; Victor K Lin; Brian C-S Liu; Arul M Chinnaiyan; Mark A Rubin; Kevin Slawin; Robert A Star; Robert H Getzenberg
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

9.  Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.

Authors:  Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

10.  Longitudinal association between prostatitis and development of benign prostatic hyperplasia.

Authors:  Jennifer L St Sauver; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; Michael M Lieber; Steven J Jacobsen
Journal:  Urology       Date:  2008-03       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.